Tái phát ngoài tủy của bệnh đa u tủy miễn dịch loại Immunoglobulin A-kappa thể hiện dưới dạng u huyết tương ở màng phổi mà không có sự tham gia của tủy xương sau khi ghép tủy xương tự thân: một báo cáo ca bệnh

Alexiou C, Kau RJ, Dietzfelbinger H, Kremer M, Spiess JC, Schratzenstaller B, Arnold W. Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. Cancer. 1999;85(11):2305–14. Luh S-P, Lai Y-S, Tsai C-H, Tsao TC-Y. Extramedullary plasmacytoma (EMP): report of a case manifested as a mediastinal mass and multiple pulmonary nodules and review of literature. World J Surg Oncol. 2007;5(1):123. Sunnetcioglu A, Ekin S, Bayram I, Ekinci O, Bugday IB. Endobronchial plasmacytoma in patient with multiple myeloma. Clin Respir J. 2017;11(6):1057–9. Alyea E, Weller E, Schlossman R, Canning C, Mauch P, Ng A, Fisher D, Gribben J, Freeman A, Parikh B, et al. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect. Bone Marrow Transpl. 2003;32(12):1145–51. Zeiser R, Deschler B, Bertz H, Finke J, Engelhardt M. Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome. Bone Marrow Transpl. 2004;34(12):1057–65. Ebrahimi A, Ahmadi H, Pourfraidon Ghasrodashti Z, Tanide N, Shahriarirad R, Erfani A, Ranjbar K, Ashkani-Esfahani S. Therapeutic effects of stem cells in different body systems, a novel method that is yet to gain trust: a comprehensive review. Bosn J Basic Med Sci. 2021;21(6):672–701. Yeoh K-W, Thitsar SM, Master Z, Loh Y, Chen Y, Nagarajan C, Tin K-M, Cutter D, Mikhaeel G. Pleural plasmacytomas-the role of radiotherapy. Br J Haematol. 2020;190(3):e160–2. Cerny J, Fadare O, Hutchinson L, Wang SA. Clinicopathological features of extramedullary recurrence/relapse of multiple myeloma. Eur J Haematol. 2008;81(1):65–9. Alegre A, Granda A, Martinez-Chamorro C, Diaz-Mediavilla J, Martinez R, Garcia-Larana J, Lahuerta JJ, Sureda A, Blade J, de la Rubia J, et al. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry. Haematologica. 2002;87(6):609–14. Terpos E, Rezvani K, Basu S, Milne AE, Rose PE, Scott GL, Rahemtulla A, Samson D, Apperley JF. Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. Eur J Haematol. 2005;75(5):376–83. Moreau P, Bataille R, Mahé B, Milpied N, Harousseau J. High-dose melphalan is not associated with extramedullary relapses in high-risk multiple myeloma. J Clin Oncol. 1993;11(9):1832–1832. Lokhorst HM, Meuwissen OJ, Verdonck LF, Dekker AW. High-risk multiple myeloma treated with high-dose melphalan. J Clin Oncol. 1992;10(1):47–51. Feng PH, Huang CC, Wang CW, Wu YK, Tsai YH. Solitary pleural plasmacytomas manifested as a massive pleural effusion without evidence of monoclonal gammopathy. Respirology. 2008;13(5):751–3. Saidane O, Slouma M, Haouet S, Abdelmoula L. Cutaneous and pleural involvement in a patient with multiple myeloma. BMJ Case Rep. 2015;2015:bcr2015211197. Al-Ataby H, Al-Tkrit A, Ali S, Seneviratne C, Omballi M. Pleural plasmacytomas in a patient with multiple myeloma relapse. Respir Med Case Reports 2022;2022:101777. Or R, Mehta J, Naparstek E, Okon E, Cividalli G, Slavin S. Successful T cell-depleted allogeneic bone marrow transplantation in a child with recurrent multiple extramedullary plasmacytomas. Bone Marrow Transpl. 1992;10(4):381–2. Verdonck LF, Lokhorst HM, Dekker AW, Nieuwenhuis HK, Petersen EJ. Graft-versus-myeloma effect in two cases. Lancet. 1996;347(9004):800–1. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood. 1996;87(3):1196–8. Annibali O, Marchesi F, Petrucci MT, Tirindelli MC, Avvisati G. Relapse of IgA λ multiple myeloma presenting as obstructive jaundice and abdominal pain. Oncol Res Treatment. 2009;32(3):119–21. Waterhouse DF, Moloney GA, Gargoum FS, Hayden PS, O’Gorman T. Extramedullary relapse of IgA-lambda myeloma after recent bortezomib therapy: a case report. Cases J. 2009;2(1):7456. Boyle EM, Fouquet G, Guidez S, Bonnet S, Demarquette H, Dulery R, Herbaux C, Noel MP, Manier S, Schraen S, et al. IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma. Cancer. 2014;120(24):3952–7. Lee CK, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J, van Rhee F, Cottler-Fox M, Muwalla F, Tricot G. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol. 2003;21(14):2732–9. Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hajek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27–38. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, Hajek R, Rosinol L, Siegel DS, Mihaylov GG, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142–52. Oxford Myeloma Group Network site specific group (NSSG)—Haematology- VDTPACE/ DTPACE [https://nssg.oxford-haematology.org.uk] NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Multiple Myeloma Version 2 [www.nccn.org/patients] Espanol I, Romera M, Gutierrez-Meca MD, Garcia MDC, Tejedor A, Martinez A, Ibanez J, De Arriba F, Minguela A, Iturbe T, et al. Carfilzomib and dexamethasone for extramedullary myeloma with pleuropericardial involvement. Clin Case Reports. 2017;5(8):1258–60. Mele G, Pastore D. Efficacy of carfilzomib, lenalidomide, and dexamethasone for extramedullary intracranial localization of multiple myeloma. Case Reports Hematol. 2018;2018:2312430.